SHIGA UNIVERSITY
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- Private
- Established
- 1949-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.shiga-u.ac.jp
Clinical Trials
13
Active:0
Completed:8
Trial Phases
4 Phases
Phase 1:7
Phase 2:1
Phase 4:2
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (11 trials with phase data)• Click on a phase to view related trials
Phase 1
7 (63.6%)Phase 4
2 (18.2%)Not Applicable
1 (9.1%)Phase 2
1 (9.1%)Night in Japan Home Sleep Monitoring Study
- Conditions
- DepressionSleep Initiation and Maintenance Disorders
- First Posted Date
- 2017-09-08
- Last Posted Date
- 2018-04-20
- Lead Sponsor
- Shiga University
- Target Recruit Count
- 2000
- Registration Number
- NCT03276585
- Locations
- 🇯🇵
Shiga University of Medical Science, Otsu, Shiga, Japan
A Study to Evaluate the Efficacy of Anti-emetic Drug Upon the Combination Chemotherapy for Non-small Cell Lung Cancer
Completed
- Conditions
- Non-small Cell Lung Cancer
- First Posted Date
- 2015-02-18
- Last Posted Date
- 2020-09-01
- Lead Sponsor
- Shiga University
- Target Recruit Count
- 10
- Registration Number
- NCT02364804
- Locations
- 🇯🇵
Shiga University of Medical Science Hospital, Otsu, Shiga, Japan
Safety and Efficacy Study of Epitope Peptide To Treat HLA-A*24 Disease Controlled Advanced Non-small Cell Lung Cancer
Phase 1
Completed
- Conditions
- Non-small Cell Lung Cancer
- First Posted Date
- 2013-09-25
- Last Posted Date
- 2019-03-19
- Lead Sponsor
- Shiga University
- Target Recruit Count
- 6
- Registration Number
- NCT01950156
- Locations
- 🇯🇵
Shiga University of Medical Science Hospital, Otsu, Shiga, Japan
Safety and Efficacy Study of Epitope Peptide To Treat HLA-A*24 or A*02-positive Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Solid Tumors
- First Posted Date
- 2013-09-24
- Last Posted Date
- 2019-03-19
- Lead Sponsor
- Shiga University
- Target Recruit Count
- 26
- Registration Number
- NCT01949688
- Locations
- 🇯🇵
Shiga University of Medical Science Hospital, Ohtsu, Shiga, Japan
Safety and Efficacy Study of Epitope Peptide To Treat HLA-A*02 Disease Controlled Advanced Non-small Cell Lung Cancer
Phase 1
Completed
- Conditions
- Non-small Cell Lung Cancer
- First Posted Date
- 2013-09-24
- Last Posted Date
- 2019-03-19
- Lead Sponsor
- Shiga University
- Target Recruit Count
- 6
- Registration Number
- NCT01949701
- Locations
- 🇯🇵
Shiga University of Medical Science Hospital, Ohtsu, Shiga, Japan
- Prev
- 1
- 2
- 3
- Next
News
No news found